Astrana Health, Inc.
ASTHNASDAQHealthcare● Active
$38.39
+$0.40(+1.05%)
Market Cap$1.9B
P/E Ratio—
52W High$39.93
52W Low$18.08
Astrana Health, Inc. (ASTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASTH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.74
Est. $0.29 · +155.2%
Revenue
$0.97B
Est. $0.95B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
ASTH reports quarterly as a NASDAQ-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.33 | — | — | — | $0.99B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.29 | $0.74 | +155.2% | $0.97B | $0.95B | +1.7% |
| ▲ Q1 FY2026 | Mar 2, 2026 | $0.15 | $0.54 | +260.0% | $0.95B | $0.93B | +2.2% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $0.47 | $0.01 | -97.9% | $0.96B | $0.93B | +2.8% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.36 | $0.19 | -47.2% | $0.65B | $0.94B | -30.6% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.23 | $0.14 | -39.1% | $0.62B | $0.63B | -1.6% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $0.22 | -$0.15 | -168.2% | $0.67B | $0.62B | +7.8% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.32 | $0.33 | +3.1% | $0.48B | $0.61B | -21.9% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.74
EPS Est.
$0.29
EPS Surpr.
+155.2%
Revenue
$0.97B
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
$0.54
EPS Est.
$0.15
EPS Surpr.
+260.0%
Revenue
$0.95B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
$0.01
EPS Est.
$0.47
EPS Surpr.
-97.9%
Revenue
$0.96B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
$0.19
EPS Est.
$0.36
EPS Surpr.
-47.2%
Revenue
$0.65B
Q2 FY2025
May 8, 2025Miss
EPS Actual
$0.14
EPS Est.
$0.23
EPS Surpr.
-39.1%
Revenue
$0.62B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.15
EPS Est.
$0.22
EPS Surpr.
-168.2%
Revenue
$0.67B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.33
EPS Est.
$0.32
EPS Surpr.
+3.1%
Revenue
$0.48B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.35 | $0.36 | $0.37 | 1 |
| Q3 FY2027 | $0.48 | $0.49 | $0.50 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.2B | $1.2B | $1.2B | 1 |
| Q3 FY2028 | $1.2B | $1.2B | $1.2B | 1 |
| Q2 FY2028 | $1.2B | $1.2B | $1.2B | 1 |
| Q1 FY2028 | $1.1B | $1.1B | $1.1B | 1 |
| Q4 FY2027 | $1.1B | $1.1B | $1.1B | 2 |
| Q3 FY2027 | $1.1B | $1.1B | $1.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +155.2% | $35.25 | $36.08 | +2.35% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +260.0% | $20.33 | $26.32 | +29.46% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -97.9% | $33.24 | $33.36 | +0.36% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -47.2% | $21.81 | $21.46 | -1.60% |
| ▼ Q2 FY2025 | May 8, 2025 | -39.1% | $32.14 | $33.44 | +4.04% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -168.2% | $35.10 | $34.68 | -1.20% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +3.1% | $59.49 | $59.08 | -0.69% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +2.6% | $47.58 | $46.36 | -2.56% |
Q2 FY2026+2.35%
Report Date
May 7, 2026
EPS Beat/Miss
+155.2%
Price Before
$35.25
Price After
$36.08
Q1 FY2026+29.46%
Report Date
Mar 2, 2026
EPS Beat/Miss
+260.0%
Price Before
$20.33
Price After
$26.32
Q4 FY2025+0.36%
Report Date
Nov 6, 2025
EPS Beat/Miss
-97.9%
Price Before
$33.24
Price After
$33.36
Q3 FY2025-1.60%
Report Date
Aug 7, 2025
EPS Beat/Miss
-47.2%
Price Before
$21.81
Price After
$21.46
Q2 FY2025+4.04%
Report Date
May 8, 2025
EPS Beat/Miss
-39.1%
Price Before
$32.14
Price After
$33.44
Q1 FY2025-1.20%
Report Date
Feb 27, 2025
EPS Beat/Miss
-168.2%
Price Before
$35.10
Price After
$34.68
Q4 FY2024-0.69%
Report Date
Nov 7, 2024
EPS Beat/Miss
+3.1%
Price Before
$59.49
Price After
$59.08
Q3 FY2024-2.56%
Report Date
Aug 7, 2024
EPS Beat/Miss
+2.6%
Price Before
$47.58
Price After
$46.36
Avg Beat Reaction+7.14%
Avg Miss Reaction+0.40%
Beat Rate4 / 8 quarters
Largest Move+29.46% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASTH ends December
Astrana Health, Inc. (ASTH) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.74 — beating the analyst consensus of $0.29 by +155.2%. ASTH has beaten EPS estimates for 2 consecutive quarters. The next ASTH earnings date is expected around September 1, 2026.
Each quarter, investors track ASTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASTH earnings · 5 questionsAstrana Health, Inc.'s next earnings report is expected around September 1, 2026. ASTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASTH historically reports after market close (AMC).
ASTH earnings datewhen is ASTH earningsASTH next earnings datewhen does ASTH report earningsASTH earnings calendar
▸ Source: FMP · Astrana Health, Inc. SEC filings · US GAAP · Astrana Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026